1,721,049 research outputs found
Analisi antropofenomenologica di un'esperienza in un'istituzione manicomiale del meridione
No full textAnthropophenomenologic analysis of an experience in a psychiatric institution of Southern Ital
Elaborazione delirante dell'esperienza di malattia in soggetto affetto da sclerosi multipla
No full textDelusional elaboration of the disease experience in a patient with multiple sclerosi
Venlafaxine: Successful treatment in impulsive disorders
No full textThis letter describes the clinical history of three patients with impulsive symptoms successfully treated with venlafaxine. Literature reports a potential efficacy of SSRI and very little information is available on new antidepressants. These cases might provide an initial piece of evidence that SNRI antidepressants can be considered in the treatment of some impulsive disorders
Depression and suicide in epilepsy: Fact or artefact?
No full textThere is evidence that depression is the most frequent
comorbid psychiatric disorder in epilepsy and a history of
depression is associated with a 4- to 6-fold greater risk of
developing epilepsy. Epilepsy, on the other hand, as a chronic
and stressful disease, represents a risk factor for developing
depression. These data suggest either a possible “bi-directional”
relationship between these two disorders or the presence of
common pathogenic mechanisms that facilitate the occurrence
of one in the presence of the other [10]. So the question is: Is
the association between depression and suicide in epilepsy a
fact or an artefact?We do not yet knowwhether a bi-directional
relationship exists between depression and epilepsy, and we
need to identify common mechanisms that facilitate depression
associated with epilepsy and epilepsy associated with
depression. We found no difference across the depression
and temporal lobe epilepsy groups in the depression
inventories and risk for suicide. Further research is needed to
clarify the impact of depressive symptoms in people with
epilepsy, such as the presence of suicidal risk factors, suicidal
ideation and suicide attempts in these patients as correlates of
depression or as psychopathological features directly associated
to epileptic disease
Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients
No full textSome studies have suggested that aripiprazole might be a useful treatment for bipolar depression. There are no studies evaluating the effect of aripiprazole on anhedonia. In the present study, effects of aripiprazole were investigated under routine clinical conditions. Anhedonia was measured in patients with bipolar disorder type I (n=50) using the self-rated Snaith-Hamilton Pleasure Scale (SHAPS) and depression was assessed using the Montgomery-Asberg Depression Rating Scale. Anhedonia was present in 52% of all patients and was significantly reduced during treatment with aripiprazole. All patients completed the 16-week trial. Only 16% of patients experienced side effects (akathisia, headache). Future studies should investigate the specificity of anti-anhedonic and anti-depressant properties of aripiprazole in bipolar patients
Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
No full textOBJECTIVE:
Several lines of research suggested that aripiprazole might be a useful treatment for acute bipolar depression. The aim of this open-label trial is to give more evidence of the clinical effectiveness and tolerability of aripiprazole in acute bipolar depression.
RESEARCH DESIGN AND METHODS:
Aripiprazole response was prospectively assessed for 16 weeks using the Montgomery-Asberg Depression Rating Scale (MADRS), the Clinical Global Impression Severity Scale (CGI-S), and the Young Mania Rating Scale in 85 bipolar patients with acute depression inadequately responsive to one mood stabilizer.
MAIN OUTCOME MEASURES:
Aripiprazole was well tolerated. Only three (3.5%) patients discontinued the study for side effects. The most common side effect was akathisia, occurring in 17/80 (21.2%) patients. Patients showed statistically insignificant weight gain (0.9 +/- 2.64 kg) over the 16-week trial.
RESULTS:
Patients showed a significant decrease in mean MADRS and CGI-S, and 80 (94.1%) patients completed the 16-week trial. Thirty-nine (45.8%) patients received aripiprazole as monotherapy and 46 received the drug adjunctively (54.1%). Fifty-two (65%) patients met criteria for response (>/= 50% reduction in MADRS total score), 30 (37.5%) patients met criteria for remission (final MADRS total score </= 12).
CONCLUSIONS:
Aripiprazole was associated with beneficial effects on mood in patients with bipolar depression, and appears well tolerated with very small changes in mean body weight. These results highlight the potential benefits of aripiprazole for bipolar disorder patients. However, double-blind, placebo-controlled studies are necessary to confirm aripiprazole's efficacy, tolerability and safety in bipolar depression
Il self-help nelle condizioni depressive: analisi dell esperienza di un gruppo di mutuo-aiuto per pazienti depressi in remissione parziale.
No full textLa gestione della crisi suicidaria: dall'emergenza clinica alla riabilitazione del paziente
No full textOmega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview.
No full textRATIONALE: Omega-3 fatty acids are known to play a role in nervous system
activity, cognitive development, memory-related learning, neuroplasticity of
nerve membranes, synaptogenesis and synaptic transmission. The brain is
considered abnormally sensitive to oxidative damage, and aging is considered one
of the most significant risk factors for degenerative neurological disorders.
Recently, clinical trials of several neurodegenerative diseases have
increasingly targeted the evaluation of the effectiveness of various
antioxidants. OBJECTIVES: The effects of omega-3 fatty acids and antioxidants on
the anatomic and functional central nervous system development and their
possible therapeutical use in some neurological and psychiatric pathologies are
evaluated. RESULTS: A number of critical trials have confirmed the benefits of
dietary supplementation with omega-3 fatty acids not only in several psychiatric
conditions, but also in inflammatory and autoimmune and neurodegenerative
diseases. Many evidences indicate that antioxidants are also essential in
maintaining a correct neurophysiology. CONCLUSIONS: Omega-3 fatty acids could be
useful in the prevention of different pathologies, such as cardiovascular,
psychiatric, neurological, dermatological and rheumatological disorders. A
number of studies suggest that antioxidants can prevent the oxidation of various
macromolecules such as DNA, proteins, and lipids. The ideal use of antioxidants
should be a prophylactic and continue treatment before aging
- …
